Sha Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Sha Li has a total of 143 co-authors. Here are the top co-authors by number of shared publications:
Huan Chen
Department of Human Anatomy, Neuroscience Research Center, Hebei Medical University, Shijiazhuang, China
17 shared publicationsChang Wang
Department of Human Anatomy, Neuroscience Research Center, Hebei Medical University, Shijiazhuang, China
13 shared publicationsHuixian Cui
Department of Human Anatomy, Neuroscience Research Center, Hebei Medical University, Shijiazhuang, China
13 shared publicationsDan Qiao
Department of Human Anatomy, Neuroscience Research Center, Hebei Medical University, Shijiazhuang, China
11 shared publications- Huixian Cui
Department of Anatomy, Hebei Medical University, Shijiazhuang, China; Neuroscience Research Center, Hebei Medical University, Shijiazhuang, China; Hebei Key Laboratory of Neurodegenerative Disease Mechanism, Shijiazhuang, China
11 shared publications Bohan Zhang
Department of Human Anatomy; Neuroscience Research Center, Hebei Medical University, Shijiazhuang 050017, China; Hebei Key Laboratory of Neurodegenerative Disease Mechanism, Shijiazhuang 050017, China
10 shared publications
Latest Publications
- 30 September 2026
- Published by Springer Nature in Neuroscience Bulletin
- p. 1-17
FMRP Regulates NrCAM Expression via β-catenin and Modulates PSD95, Dendritic Spines and Autism-like Behaviors
- 30 September 2026
- Published by Springer Nature in Neuroscience Bulletin
- p. 1-17
FMRP Regulates NrCAM Expression via β-catenin and Modulates PSD95, Dendritic Spines and Autism-like Behaviors
- 20 June 2026
- Published by Springer Nature in Journal of Neurology
- Vol. 273 (7) , 409
Plasma p-Tau217 and Aβ42/Aβ40 mediate the association between minimal depressive symptoms and cognitive impairment
Depression is a recognized risk factor and potential prodromal feature of Alzheimer's disease (AD). While associations between depressive symptoms and AD pathology have been observed using cerebrospinal fluid (CSF) and PET imaging, it remains unclear whether these relationships can be captured by accessible plasma biomarkers, particularly the highly specific phosphorylated tau-217 (p-Tau217). We analyzed 615 participants from Alzheimer's disease Neuroimaging Initiative (ADNI) cohort, of whom 374 had minimal depressive symptoms (MDS). Plasma biomarkers included phosphorylated tau-217 (p-Tau217), amyloid-β 42/40 ratio (Aβ42/Aβ40), neurofilament light chain (NfL), and glial fibrillary acidic protein (GFAP). Linear regression models and mediation analyses were employed to examine associations between MDS, plasma biomarkers (p-Tau217, Aβ42/Aβ40, NfL, and GFAP), and cognitive impairment, with adjustments for age, sex, and APOE ε4 carrier status. Participants with MDS demonstrated significantly elevated plasma p-Tau217 levels (mean difference = 0.105, 95% CI [0.046, 0.163]; P < 0.001) and reduced Aβ42/Aβ40 (mean difference = −0.024, 95% CI [−0.041, −0.006]; P = 0.007) compared with those without MDS. These associations were primarily observed in non-demented individuals and influenced by age, sex, and APOE ε4 status. In mediation analyses, plasma p-Tau217 accounted for 41.57%-42.18% of the association between MDS and cognitive impairment, while Aβ42/Aβ40 mediated 7.13%-8.45% of this relationship. Plasma biomarkers of p-Tau217 and Aβ42/Aβ40 were associated with early depressive symptoms and mediate their associations with cognitive impairment. These findings identify plasma p-Tau217 as a key mediator linking MDS to cognitive impairment, extending evidence from CSF to accessible blood-based biomarkers. This highlights the value of monitoring plasma p-Tau217 and Aβ42/Aβ40 to unravel the pathological basis of depressive symptoms in early AD.
- 20 June 2026
- Published by Springer Nature in Journal of Neurology
- Vol. 273 (7) , 409
Plasma p-Tau217 and Aβ42/Aβ40 mediate the association between minimal depressive symptoms and cognitive impairment
Depression is a recognized risk factor and potential prodromal feature of Alzheimer's disease (AD). While associations between depressive symptoms and AD pathology have been observed using cerebrospinal fluid (CSF) and PET imaging, it remains unclear whether these relationships can be captured by accessible plasma biomarkers, particularly the highly specific phosphorylated tau-217 (p-Tau217). We analyzed 615 participants from Alzheimer's disease Neuroimaging Initiative (ADNI) cohort, of whom 374 had minimal depressive symptoms (MDS). Plasma biomarkers included phosphorylated tau-217 (p-Tau217), amyloid-β 42/40 ratio (Aβ42/Aβ40), neurofilament light chain (NfL), and glial fibrillary acidic protein (GFAP). Linear regression models and mediation analyses were employed to examine associations between MDS, plasma biomarkers (p-Tau217, Aβ42/Aβ40, NfL, and GFAP), and cognitive impairment, with adjustments for age, sex, and APOE ε4 carrier status. Participants with MDS demonstrated significantly elevated plasma p-Tau217 levels (mean difference = 0.105, 95% CI [0.046, 0.163]; P < 0.001) and reduced Aβ42/Aβ40 (mean difference = −0.024, 95% CI [−0.041, −0.006]; P = 0.007) compared with those without MDS. These associations were primarily observed in non-demented individuals and influenced by age, sex, and APOE ε4 status. In mediation analyses, plasma p-Tau217 accounted for 41.57%-42.18% of the association between MDS and cognitive impairment, while Aβ42/Aβ40 mediated 7.13%-8.45% of this relationship. Plasma biomarkers of p-Tau217 and Aβ42/Aβ40 were associated with early depressive symptoms and mediate their associations with cognitive impairment. These findings identify plasma p-Tau217 as a key mediator linking MDS to cognitive impairment, extending evidence from CSF to accessible blood-based biomarkers. This highlights the value of monitoring plasma p-Tau217 and Aβ42/Aβ40 to unravel the pathological basis of depressive symptoms in early AD.
- Open Access
- 6 April 2026
- Published by Wiley in Alzheimer's & Dementia
- Vol. 22 (4) , e71349
Accelerated epigenetic aging as a modifier of homocysteine‐associated cognitive decline: Findings from NHANES
INTRODUCTION: Hyperhomocysteinemia represents a modifiable risk factor for cognitive decline and dementia, yet the role of epigenetic aging mechanisms in mediating this association remain poorly characterized, limiting development of targeted interventions. METHODS: We analyzed 1343 National Health and Nutrition Examination Survey participants aged ≥ 60 years using weighted regression, cubic splines, and mediation analyses. An independent cohort of 2073 participants validated findings. RESULTS: Elevated homocysteine concentrations were significantly associated with reduced cognitive processing speed. GrimAge2 epigenetic age acceleration significantly mediated this association, accounting for 33.3% of the total effect. β2‐microglobulin emerged as the strongest mediating component, explaining 38.8% of the homocysteine–cognition relationship. Folate demonstrated cognitive protection through homocysteine reduction (18.7% of total effect) without modulating downstream pathological cascades. CONCLUSION: Epigenetic aging‐associated neuroinflammation serves as a key mechanistic link between hyperhomocysteinemia and cognitive decline. The neuroprotective effects of folate are mediated specifically through homocysteine reduction, providing novel mechanistic insights for precision prevention strategies in cognitive aging.
- 6 April 2026
- Published by Wiley in Alzheimer's & Dementia
- Vol. 22 (4) , e71349
Open AccessAccelerated epigenetic aging as a modifier of homocysteine‐associated cognitive decline: Findings from NHANES
INTRODUCTION: Hyperhomocysteinemia represents a modifiable risk factor for cognitive decline and dementia, yet the role of epigenetic aging mechanisms in mediating this association remain poorly characterized, limiting development of targeted interventions. METHODS: We analyzed 1343 National Health and Nutrition Examination Survey participants aged ≥ 60 years using weighted regression, cubic splines, and mediation analyses. An independent cohort of 2073 participants validated findings. RESULTS: Elevated homocysteine concentrations were significantly associated with reduced cognitive processing speed. GrimAge2 epigenetic age acceleration significantly mediated this association, accounting for 33.3% of the total effect. β2‐microglobulin emerged as the strongest mediating component, explaining 38.8% of the homocysteine–cognition relationship. Folate demonstrated cognitive protection through homocysteine reduction (18.7% of total effect) without modulating downstream pathological cascades. CONCLUSION: Epigenetic aging‐associated neuroinflammation serves as a key mechanistic link between hyperhomocysteinemia and cognitive decline. The neuroprotective effects of folate are mediated specifically through homocysteine reduction, providing novel mechanistic insights for precision prevention strategies in cognitive aging.
- 5 March 2026
- Published by Springer Nature in Journal of Neurology
- Vol. 273 (3) , 183
Plasma p-tau217 assays effectively predict amyloid status but lack precision for tau staging in Alzheimer’s disease
Blood-based biomarkers for Alzheimer's disease (AD) have demonstrated high performance in identifying amyloid-β (Aβ) pathology. However, the diagnostic accuracy of commercial plasma biomarker assays in predicting PET-defined AD stages—particularly late-stage tau accumulation—requires further evaluation. We included 229 participants from the Alzheimer's Disease Neuroimaging Initiative, all of whom underwent amyloid and tau PET imaging and testing with plasma assays. Among the plasma biomarkers, p-tau217 showed the strongest linear and non-linear associations with amyloid and tau PET. When distinguishing A + from A − T − participants, p-tau217 assays achieved the highest accuracy (AUC range: 0.85–0.91), outperforming other plasma biomarkers (AUC range: 0.66–0.81). However, the accuracy of plasma biomarkers, including p-tau217 assays, significantly decreased when differentiating A + T + from A + T − stages (AUC for p-tau217 assays: 0.69–0.77; AUC for other plasma biomarkers: 0.53–0.67; P < 0.05). These findings were replicated in an independent cohort (n = 334). Our study found that among currently available commercial plasma assays, including p-tau217 assays, they demonstrate high accuracy in classifying Aβ status but are less accurate in assessing tau pathology severity in Aβ positive individuals.
- 5 March 2026
- Published by Springer Nature in Journal of Neurology
- Vol. 273 (3) , 183
Plasma p-tau217 assays effectively predict amyloid status but lack precision for tau staging in Alzheimer’s disease
Blood-based biomarkers for Alzheimer's disease (AD) have demonstrated high performance in identifying amyloid-β (Aβ) pathology. However, the diagnostic accuracy of commercial plasma biomarker assays in predicting PET-defined AD stages—particularly late-stage tau accumulation—requires further evaluation. We included 229 participants from the Alzheimer's Disease Neuroimaging Initiative, all of whom underwent amyloid and tau PET imaging and testing with plasma assays. Among the plasma biomarkers, p-tau217 showed the strongest linear and non-linear associations with amyloid and tau PET. When distinguishing A + from A − T − participants, p-tau217 assays achieved the highest accuracy (AUC range: 0.85–0.91), outperforming other plasma biomarkers (AUC range: 0.66–0.81). However, the accuracy of plasma biomarkers, including p-tau217 assays, significantly decreased when differentiating A + T + from A + T − stages (AUC for p-tau217 assays: 0.69–0.77; AUC for other plasma biomarkers: 0.53–0.67; P < 0.05). These findings were replicated in an independent cohort (n = 334). Our study found that among currently available commercial plasma assays, including p-tau217 assays, they demonstrate high accuracy in classifying Aβ status but are less accurate in assessing tau pathology severity in Aβ positive individuals.
- Open Access
- 23 January 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Activation of LH orexin neurons and VTA dopamine neurons is involved in anesthesia/surgery-induced sleep–wake disorders and delirium-like behaviors in mice
Postoperative delirium (POD) and sleep disorders are common surgical complications with a close clinical association, suggesting shared pathophysiological mechanisms mediated by neurotransmitters and neural circuits. Using a mouse model of laparotomy under sevoflurane anesthesia, we assessed delirium-like behaviors (buried food, open field, and Y-maze tests) and sleep alterations (EEG/EMG). Hypothalamic orexin A and midbrain dopamine levels were measured by ELISA. Neural activation was evaluated via c-Fos immunohistochemistry and immunofluorescence staining of lateral hypothalamus (LH) orexin and ventral tegmental area (VTA) dopamine neurons. Tyrosine hydroxylase (TH) expression in the VTA was detected by Western blot. Anesthesia/surgery induced sleep disorders, altered sleep–wake architecture and delirium-like behaviors. Following anesthesia/surgery, c-Fos protein expression was increased in neurons of the LH and ventromedial hypothalamic nucleus (VMH), while it was decreased in sleep-promoting brain regions, including the ventrolateral preoptic area (VLPO) and median preoptic nucleus (MnPO). Additionally, anesthesia/surgery led to increased activation of orexin neurons in the LH and dopamine neurons in the VTA. Hypothalamic orexin A levels and midbrain dopamine concentrations were elevated, along with increased tyrosine hydroxylase (TH) expression in the VTA. Administration of the dual orexin receptor antagonist suvorexant via intraperitoneal injection reduced the activation of VTA dopamine neurons, decreased TH expression, and lowered dopamine levels in these mice. The activation of LH orexin neurons and VTA dopamine neurons is involved in anesthesia/surgery-induced sleep–wake disorders and delirium-like behaviors. The dual orexin receptor antagonist suvorexant ameliorates these abnormalities, highlighting a potential therapeutic target.
- 23 January 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Open AccessActivation of LH orexin neurons and VTA dopamine neurons is involved in anesthesia/surgery-induced sleep–wake disorders and delirium-like behaviors in mice
Postoperative delirium (POD) and sleep disorders are common surgical complications with a close clinical association, suggesting shared pathophysiological mechanisms mediated by neurotransmitters and neural circuits. Using a mouse model of laparotomy under sevoflurane anesthesia, we assessed delirium-like behaviors (buried food, open field, and Y-maze tests) and sleep alterations (EEG/EMG). Hypothalamic orexin A and midbrain dopamine levels were measured by ELISA. Neural activation was evaluated via c-Fos immunohistochemistry and immunofluorescence staining of lateral hypothalamus (LH) orexin and ventral tegmental area (VTA) dopamine neurons. Tyrosine hydroxylase (TH) expression in the VTA was detected by Western blot. Anesthesia/surgery induced sleep disorders, altered sleep–wake architecture and delirium-like behaviors. Following anesthesia/surgery, c-Fos protein expression was increased in neurons of the LH and ventromedial hypothalamic nucleus (VMH), while it was decreased in sleep-promoting brain regions, including the ventrolateral preoptic area (VLPO) and median preoptic nucleus (MnPO). Additionally, anesthesia/surgery led to increased activation of orexin neurons in the LH and dopamine neurons in the VTA. Hypothalamic orexin A levels and midbrain dopamine concentrations were elevated, along with increased tyrosine hydroxylase (TH) expression in the VTA. Administration of the dual orexin receptor antagonist suvorexant via intraperitoneal injection reduced the activation of VTA dopamine neurons, decreased TH expression, and lowered dopamine levels in these mice. The activation of LH orexin neurons and VTA dopamine neurons is involved in anesthesia/surgery-induced sleep–wake disorders and delirium-like behaviors. The dual orexin receptor antagonist suvorexant ameliorates these abnormalities, highlighting a potential therapeutic target.
- Open Access
- 22 January 2026
- Published by Wiley in CNS Neuroscience & Therapeutics
- Vol. 32 (1) , e70748
Intermittent Fasting Alleviates Anesthesia/Surgery‐Induced Delirium‐Like Behavior in Aged Mice by Remodeling Gut Microbiota
Background: Postoperative delirium (POD) is a serious complication in elderly patients, associated with prolonged recovery and adverse outcomes. Recent evidence links POD to mitochondrial dysfunction. While intermittent fasting (IF) has been shown to enhance mitochondrial function and exert neuroprotective effects, potentially through gut microbiota modulation, its ability to prevent POD and the underlying mechanisms remain unclear. Methods: We examined the effects of preoperative IF on delirium‐like behavior in aged mice following anesthesia/surgery. Assessments included neurobehavioral tests, gut microbiota composition, fecal shortchain fatty acids (SCFAs), hippocampal synaptic and mitochondrial ultrastructure via transmission electron microscopy, mitochondrial function, and related molecular markers. To establish causality, fecal microbiota transplantation and SCFA supplementation experiments were conducted. Results: Preoperative IF significantly attenuated anesthesia/surgery‐induced delirium‐like behaviors. Mechanistically, IF reshaped the gut microbiota and preserved SCFA levels, which collectively maintained hippocampal mitochondrial homeostasis. Both fecal microbiota transplantation and SCFA supplementation replicated the protective effects of IF, confirming the causal role of gut microbiota and its metabolites. Conclusion: These findings demonstrate that preoperative intermittent fasting mitigates delirium‐like behavior by modulating the gut microbiota–SCFA–mitochondrial axis, highlighting its potential as a non‐pharmacological strategy to enhance neurocognitive resilience and prevent POD in elderly surgical patients.
- 22 January 2026
- Published by Wiley in CNS Neuroscience & Therapeutics
- Vol. 32 (1) , e70748
Open AccessIntermittent Fasting Alleviates Anesthesia/Surgery‐Induced Delirium‐Like Behavior in Aged Mice by Remodeling Gut Microbiota
Background: Postoperative delirium (POD) is a serious complication in elderly patients, associated with prolonged recovery and adverse outcomes. Recent evidence links POD to mitochondrial dysfunction. While intermittent fasting (IF) has been shown to enhance mitochondrial function and exert neuroprotective effects, potentially through gut microbiota modulation, its ability to prevent POD and the underlying mechanisms remain unclear. Methods: We examined the effects of preoperative IF on delirium‐like behavior in aged mice following anesthesia/surgery. Assessments included neurobehavioral tests, gut microbiota composition, fecal shortchain fatty acids (SCFAs), hippocampal synaptic and mitochondrial ultrastructure via transmission electron microscopy, mitochondrial function, and related molecular markers. To establish causality, fecal microbiota transplantation and SCFA supplementation experiments were conducted. Results: Preoperative IF significantly attenuated anesthesia/surgery‐induced delirium‐like behaviors. Mechanistically, IF reshaped the gut microbiota and preserved SCFA levels, which collectively maintained hippocampal mitochondrial homeostasis. Both fecal microbiota transplantation and SCFA supplementation replicated the protective effects of IF, confirming the causal role of gut microbiota and its metabolites. Conclusion: These findings demonstrate that preoperative intermittent fasting mitigates delirium‐like behavior by modulating the gut microbiota–SCFA–mitochondrial axis, highlighting its potential as a non‐pharmacological strategy to enhance neurocognitive resilience and prevent POD in elderly surgical patients.
- 15 November 2025
- Published by Springer Nature in Molecular Neurobiology
- Vol. 63 (1) , 47
CSF Glucose-6-Phosphate Isomerase Is a Tau-Related Biomarker Associated with Neurodegeneration and Cognitive Impairment in Alzheimer’s Disease
Skeletal diseases are closely linked to Alzheimer’s disease (AD) in terms of epidemiology and pathogenesis. Glucose-6-phosphate isomerase (GPI), a critical enzyme in the glycolytic pathway that participates in various skeletal disorders, has unclear effects on AD pathological progression in humans. This cross-sectional study included 601 participants from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) [260 (43.3%) women; 288 (47.9%) APOE ε4 carriers]. The cohort comprised 151 cognitively normal (CN) participants [mean age 74.7 (5.9) years] and 450 cognitively impaired (CI) participants [mean age 72.8 (7.8) years]. We assessed CSF GPI levels, AD biomarkers (CSF β-amyloid [Aβ]42, phosphorylated Tau [p-Tau]181), magnetic resonance imaging-based neurodegenerative changes, and cognitive function. Associations between CSF GPI levels and AD pathology, neurodegeneration, and cognition were evaluated using linear regression models. Mediation models were employed to investigate the potential mechanism of how CSF GPI affects AD pathology. Findings were validated in two independent external cohorts using autopsy-confirmed Braak staging (n = 419; mean age 84.1 [6.6] years; 195 [46.5%] women) and cross-platform validation (n = 36). Among the total cohort (N = 601), CSF GPI levels were significantly elevated among participants with tau pathology (T+ group), regardless of Aβ status, and correlated positively with CSF p-Tau181 but not with Aβ42. Higher CSF GPI levels were also associated with downstream events of tau pathology, including reduced hippocampal volume and worse cognitive performance. Mediation analyses revealed that CSF GPI partially mediated tau pathology’s effects on hippocampal volume reduction and cognitive impairment. Moreover, CSF GPI exhibited excellent diagnostic accuracy in distinguishing tau-positive/negative (T+/−) participants (area under the curve [AUC] = 0.833), with even higher accuracy when combined with demographic indicators (AUC = 0.862). In the external cohort, we used Braak staging of neuropathologies found at autopsy to indicate tau pathology and validated its positive association with CSF GPI levels (p < 0.001), with cross-platform validation demonstrating strong concordance of GPI measurements between different analytical methods (r = 0.817, p < 0.001). CSF GPI shows associations with tau pathology independent of amyloid status and may partially mediate relationships between tau pathological changes and neurodegeneration. These findings indicate that CSF GPI may serve as a potential biomarker reflecting tau-related pathological processes. However, further validation studies are required to establish its utility for clinical diagnostic evaluation or therapeutic monitoring.
- 15 November 2025
- Published by Springer Nature in Molecular Neurobiology
- Vol. 63 (1) , 47
CSF Glucose-6-Phosphate Isomerase Is a Tau-Related Biomarker Associated with Neurodegeneration and Cognitive Impairment in Alzheimer’s Disease
Skeletal diseases are closely linked to Alzheimer’s disease (AD) in terms of epidemiology and pathogenesis. Glucose-6-phosphate isomerase (GPI), a critical enzyme in the glycolytic pathway that participates in various skeletal disorders, has unclear effects on AD pathological progression in humans. This cross-sectional study included 601 participants from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) [260 (43.3%) women; 288 (47.9%) APOE ε4 carriers]. The cohort comprised 151 cognitively normal (CN) participants [mean age 74.7 (5.9) years] and 450 cognitively impaired (CI) participants [mean age 72.8 (7.8) years]. We assessed CSF GPI levels, AD biomarkers (CSF β-amyloid [Aβ]42, phosphorylated Tau [p-Tau]181), magnetic resonance imaging-based neurodegenerative changes, and cognitive function. Associations between CSF GPI levels and AD pathology, neurodegeneration, and cognition were evaluated using linear regression models. Mediation models were employed to investigate the potential mechanism of how CSF GPI affects AD pathology. Findings were validated in two independent external cohorts using autopsy-confirmed Braak staging (n = 419; mean age 84.1 [6.6] years; 195 [46.5%] women) and cross-platform validation (n = 36). Among the total cohort (N = 601), CSF GPI levels were significantly elevated among participants with tau pathology (T+ group), regardless of Aβ status, and correlated positively with CSF p-Tau181 but not with Aβ42. Higher CSF GPI levels were also associated with downstream events of tau pathology, including reduced hippocampal volume and worse cognitive performance. Mediation analyses revealed that CSF GPI partially mediated tau pathology’s effects on hippocampal volume reduction and cognitive impairment. Moreover, CSF GPI exhibited excellent diagnostic accuracy in distinguishing tau-positive/negative (T+/−) participants (area under the curve [AUC] = 0.833), with even higher accuracy when combined with demographic indicators (AUC = 0.862). In the external cohort, we used Braak staging of neuropathologies found at autopsy to indicate tau pathology and validated its positive association with CSF GPI levels (p < 0.001), with cross-platform validation demonstrating strong concordance of GPI measurements between different analytical methods (r = 0.817, p < 0.001). CSF GPI shows associations with tau pathology independent of amyloid status and may partially mediate relationships between tau pathological changes and neurodegeneration. These findings indicate that CSF GPI may serve as a potential biomarker reflecting tau-related pathological processes. However, further validation studies are required to establish its utility for clinical diagnostic evaluation or therapeutic monitoring.
- 18 April 2025
- Published by Elsevier in Phytomedicine
- Vol. 142, 156781
Morusin ameliorates tubulointerstitial damage in diabetic mice through SIRT1/HIF-1α/IL-16 signaling pathway
- 18 April 2025
- Published by Elsevier in Phytomedicine
- Vol. 142, 156781
Morusin ameliorates tubulointerstitial damage in diabetic mice through SIRT1/HIF-1α/IL-16 signaling pathway
- 17 April 2025
- Published by Elsevier in Geriatric Nursing
- Vol. 63, 395-406
The effects of methyl nutrients on cognition and one carbon metabolism in older adults with mild cognitive impairment, A systematic review and meta-analysis
- 17 April 2025
- Published by Elsevier in Geriatric Nursing
- Vol. 63, 395-406
The effects of methyl nutrients on cognition and one carbon metabolism in older adults with mild cognitive impairment, A systematic review and meta-analysis
- Open Access
- 16 April 2025
- Published by Frontiers Media SA in Frontiers in Aging Neuroscience
- Vol. 17, 1572976
Effects of m6A methylation of MAT2A mRNA regulated by METTL16 on learning and memory, hippocampal synaptic plasticity and Aβ1–42 in 5 × FAD mice
Background: Alzheimer’s disease (AD) is a common neurodegenerative disorder affecting older adults, characterized by progressive cognitive decline and pathological features such as amyloid plaque deposition, neuronal loss, and synaptic reduction. RNA N6-methyladenosine (m6A) methylation is prevalent in the brain and is intricately linked to synaptic plasticity, learning, and memory in AD. However, the precise mechanisms underlying these associations remain elusive.Methods: This study employed the overexpression of methyltransferase-like protein 16 (METTL16), or overexpression of methionine adenosyltransferase 2A (MAT2A), or a combination of METTL16 overexpression with MAT2A knockdown to explore the influence of METTL16 on the regulation of MAT2A in cognitive function, hippocampal synaptic plasticity, and amyloid-beta (Aβ1–42) metabolism in 5 × FAD mice.Results: Our findings indicated a reduction in m6A methylation levels and the expression of METTL16 and MAT2A in the hippocampus of 5 × FAD mice. Overexpression of METTL16 led to an increase in overall m6A methylation levels, furthermore, overexpression of either METTL16 or MAT2A enhanced learning and memory in 5 × FAD mice, elevated the expression levels of postsynaptic density 95 (PSD95) and synaptophysin (Syp), increased dendritic spine density, and decreased the accumulation of Aβ1–42 in the hippocampus. In the hippocampus of 5 × FAD mice, METTL16 was found to upregulate both the protein and mRNA levels of MAT2A, as well as enhance MAT2A mRNA m6A methylation levels. Concurrent, overexpression of METTL16 and knockdown of MAT2A in the hippocampus resulted in impaired learning and memory in 5 × FAD mice, alongside a reduction in synaptic protein expression and dendritic spine density, and an increase in Aβ1–42 accumulation.Conclusion: The present study demonstrated that METTL16 enhances learning and memory in 5 × FAD mice by regulating MAT2A mRNA m6A methylation, which leads to increased expression levels of PSD95 and Syp, greater dendritic spine density, and reduced Aβ1–42 accumulation in the hippocampus. These findings reveal a novel approach for investigating the pathophysiological role of METTL16 in AD and offer new insights for developing of potential therapeutic targets for AD.
- 16 April 2025
- Published by Frontiers Media SA in Frontiers in Aging Neuroscience
- Vol. 17, 1572976
Open AccessEffects of m6A methylation of MAT2A mRNA regulated by METTL16 on learning and memory, hippocampal synaptic plasticity and Aβ1–42 in 5 × FAD mice
Background: Alzheimer’s disease (AD) is a common neurodegenerative disorder affecting older adults, characterized by progressive cognitive decline and pathological features such as amyloid plaque deposition, neuronal loss, and synaptic reduction. RNA N6-methyladenosine (m6A) methylation is prevalent in the brain and is intricately linked to synaptic plasticity, learning, and memory in AD. However, the precise mechanisms underlying these associations remain elusive.Methods: This study employed the overexpression of methyltransferase-like protein 16 (METTL16), or overexpression of methionine adenosyltransferase 2A (MAT2A), or a combination of METTL16 overexpression with MAT2A knockdown to explore the influence of METTL16 on the regulation of MAT2A in cognitive function, hippocampal synaptic plasticity, and amyloid-beta (Aβ1–42) metabolism in 5 × FAD mice.Results: Our findings indicated a reduction in m6A methylation levels and the expression of METTL16 and MAT2A in the hippocampus of 5 × FAD mice. Overexpression of METTL16 led to an increase in overall m6A methylation levels, furthermore, overexpression of either METTL16 or MAT2A enhanced learning and memory in 5 × FAD mice, elevated the expression levels of postsynaptic density 95 (PSD95) and synaptophysin (Syp), increased dendritic spine density, and decreased the accumulation of Aβ1–42 in the hippocampus. In the hippocampus of 5 × FAD mice, METTL16 was found to upregulate both the protein and mRNA levels of MAT2A, as well as enhance MAT2A mRNA m6A methylation levels. Concurrent, overexpression of METTL16 and knockdown of MAT2A in the hippocampus resulted in impaired learning and memory in 5 × FAD mice, alongside a reduction in synaptic protein expression and dendritic spine density, and an increase in Aβ1–42 accumulation.Conclusion: The present study demonstrated that METTL16 enhances learning and memory in 5 × FAD mice by regulating MAT2A mRNA m6A methylation, which leads to increased expression levels of PSD95 and Syp, greater dendritic spine density, and reduced Aβ1–42 accumulation in the hippocampus. These findings reveal a novel approach for investigating the pathophysiological role of METTL16 in AD and offer new insights for developing of potential therapeutic targets for AD.